Allogeneic BMT in patients above 45 years of age: a single center experience.
Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT in our institution over the preceding 4 years. Pretransplant conditioning consisted of Bu/CY2, GVHD prophylaxis of a combination of cyclosporine and "short" methotrexate. At present 54% of patients remain alive (with a median follow-up 44 months), the probability of survival at 5 years is 53% (5-year DFS 78%). The 5-year survival probability in the control group of younger patients is 53% (P = 0.8003). Main causes of death were GVHD (4 patients, 10%), relapse (5 patients, 13%) and infection (6 patients, 15%). The incidence of acute GVHD grade II-IV was 51% (grade III-IV 0% patients), the incidence of chronic GVHD 49% (limited 18% and extensive 31% patients). Our results suggest that allogeneic BMT can be performed in patients above the age of 45 years with acceptable morbidity and mortality, especially if a family HLA matched donor is available.
Lysák
D
D
Department of Haematology and Oncology, Charles University Hospital Pilsen, Alej Svovody 80, 304 60 Pilsen, Czech Republic.
Koza
V
V
Jindra
P
P
Vozobulová
V
V
Schutzová
M
M
Fiser
J
J
Cerná
K
K
Karas
M
M
Skopek
P
P
Svojgrová
M
M
Vokurka
S
S
D000206:Actuarial Analysis; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000379:methods / Q000401:mortality*; D002423:Cause of Death; D005260:Female; D006086:Graft vs Host Disease / Q000145:classification; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000379:methods / Q000401:mortality